Holen Sie sich die Stockscreener-App
0.00
100.00%
-104.91
Schlusskurs vom Vortag:
$104.91
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$20.03B
Einnahmen:
$3.25B
Nettoeinkommen (Verlust:
$-207.95M
KGV:
0.00
EPS:
-1.1046
Netto-Cashflow:
$356.78M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$104.98
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
0.00 | 20.03B | 3.25B | -207.95M | 356.78M | -1.1046 |
TMO
Thermo Fisher Scientific Inc
|
492.51 | 181.06B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
182.67 | 127.84B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
563.53 | 44.81B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.53 | 38.21B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
383.57 | 36.00B | 3.77B | 449.25M | 240.68M | 7.8556 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Exact Sciences Corp stock (US30063P1057): Nasdaq-listed cancer diagnostics group steady after recent - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Abbott buyout clouds listing status and sector role - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Abbott deal reshapes outlook for cancer diagnostics leade - AD HOC NEWS
Canaccord Genuity Downgrades Exact Sciences (EXAS) - MSN
Exact Sciences stock (US30063P1057): Diagnostics peer update after Petrichor hiring - AD HOC NEWS
Exact Sciences stock (US30063P1057): screening business, oncology focus, and what U.S. investors are - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): diagnostics specialist in focus after leadership news - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): earnings backdrop and cancer diagnostics focus - AD HOC NEWS
Exact Sciences Corp stock (US30063P1057): acquisition plans stir debate around growth and dilution - AD HOC NEWS
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know - TradingKey
Exact Sciences stock (US30063P1057): latest business update and investor focus - AD HOC NEWS
TD Cowen Maintains Exact Sciences (EXAS) Buy Recommendation - MSN
Exact Sciences stock (US30063P1057): Screening leader faces a new investor test - AD HOC NEWS
Is Abbott’s Exact Sciences Deal And Nutrition Pivot Altering The Investment Case For Abbott (ABT)? - Yahoo Finance
Exact Sciences Corp. stock (US30063P1057): earnings beat and Abbott takeover reshape cancer diagnost - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B - AD HOC NEWS
Exact Sciences stock (US30063P1057): Q1 2026 revenue growth driven by Cologuard and Oncotype DX - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Risk channels signal institutional focus - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Q1 2026 earnings and screening advancements - AD HOC NEWS
BTIG Downgrades Exact Sciences (EXAS) - MSN
Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue up 23% - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue growth - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Q4 2025 earnings miss on EPS despite revenue beat - AD HOC NEWS
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - MSN
Exact Sciences Corp. Stock (US30063P1057): Q1 2026 Earnings Release Scheduled for May 7 - AD HOC NEWS
Kevin Conroy (ABBOTT LABORATORIES: ABT) reports 131,451-share Form 3 holding - Stock Titan
Abbott Laboratories Stock (ABT) Opinions on Q1 Earnings and Exact Sciences Acquisition - Quiver Quantitative
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits - MSN
Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account - Investing.com India
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock - AD HOC NEWS
Abbott Laboratories Slammed On Its Post-Exact Sciences Guidance - Investor's Business Daily
Abbott trims 2026 profit forecast on Exact deal hit, shares fall - Reuters
Q1 progress positions Abbott for accelerating growth in 2026 - Abbott
Abbott Cuts Profit Forecast After $21 Billion Deal, Shares Fall 4.6% - TradingView
Abbott cuts profit forecast in wake of Exact Sciences deal - Modern Healthcare
Abbott cuts 2026 profit forecast on Exact deal, shares fall - BioWorld News
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag - Yahoo! Finance Canada
Earnings call transcript: Abbott Labs Q1 2026 results align with expectations - Investing.com
Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know - TradingKey
Abbott reports Q1 earnings, completes Exact Sciences acquisition - Investing.com
Abbott lowers earnings forecast after $21B Exact Sciences buy - Yahoo Finance
Abbott results beat on medical device boost, Exact deal hits forecast - Yahoo Finance
Abbott (ABT) Q1 2026 earnings rise on adjusted basis after Exact Sciences acquisition - Stock Titan
Abbott adds Exact Sciences, expands into fast-growing cancer tests - Stock Titan
Abbott’s Exact acquisition drives med-tech M&A to $23.7B in March - BioWorld News
Abbott Verdict And Exact Sciences Deal Reshape Risk And Growth Outlook - Yahoo Finance
Exact Sciences to Participate in June Investor Conferences - Yahoo
Abbott’s $23 billion Exact Sciences deal revives diagnostics growth ambitions - S&P Global
Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus - AD HOC NEWS
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):